Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.
The conversation discusses the use of RU58841 for hair loss, with concerns about its legality in Germany and potential legal consequences. Alternatives like finasteride and dutasteride are mentioned, with some users questioning the effectiveness and safety of RU58841.
A user is considering using both oral and topical finasteride for hair loss, despite having elevated liver enzymes. They currently use a topical spray with finasteride and minoxidil and are seeking advice on whether using both forms is advisable.
The user "StrummerBummer" has been taking finasteride for 25 years without side effects, but is now switching to dutasteride. Other users congratulate and support the decision.
PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.
The conversation is about finding a legitimate and affordable Chinese source for RU58841 powder for hair loss treatment. It suggests choosing a vendor with good reviews and testing the product for authenticity.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.
The user reported significant hair regrowth using a topical treatment of 0.3% finasteride and 6% minoxidil, with noticeable progress in five months. The treatment is applied once daily, and the user experienced some initial shedding but no side effects.
A user shared progress pictures showing hairline improvement after using oral finasteride (1mg) and minoxidil (3mg) for 5 months. Replies praised the noticeable regrowth and encouraged continued use.
A user's experience of using finasteride to treat hair loss, including details about shedding and side effects; their regimen; and the advice given by others about diet, sport, smoking, and topical treatments.
A user shared their 2-month progress on finasteride 1mg daily and weekly derma rolling, showing noticeable hair regrowth. Replies confirm visible improvement, though some attribute it partially to lighting.
Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.
OP underwent a hair transplant (HT) and has been using finasteride for one year. Despite having thin hair, OP is happy with the results and feels more confident.
Significant hair regrowth was achieved using oral finasteride and topical minoxidil over five months, with noticeable improvements in hairline and temple areas. The user experienced minimal side effects, mainly increased eyebrow and eyelash growth, and attributes additional physical improvements to weight loss and exercise.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.
Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
The user experienced significant hair regrowth and reduced hair loss using finasteride 1mg daily and minoxidil 5% twice a day. Finasteride stopped 90% of hair loss and thickened hair, while minoxidil regrew hair, with minimal side effects reported.
The user has been taking oral finasteride for 2 months, experiencing more hair loss but noticing some fuzzy hair growth on the scalp. They are questioning if this new hair growth is significant.
Dutasteride might be better for hairline due to varying levels of 5AR activity in scalps. Genetic tests can determine if finasteride is enough or if dutasteride is needed.
A user experienced a hard lump under their nipple and increased hair loss after four months of finasteride. They are concerned about the lump and plan to stop the treatment.
LLLT (low-level laser therapy) is as effective or better than traditional minoxidil treatment for hair growth, with fewer side effects and improved long-term compliance due to milder adverse effects. Studies show LLLT increases hair density more than minoxidil, but drawbacks include the initial cost and the need for long-term use to see results.